Current approaches to pharmacotherapy for smoking cessation.
Current approaches to pharmacotherapy for smoking cessation.
复制标题
DOI：
10.1177/1753465809353768
复制
发表时间：
2010-02-01
影响因子：
4.3
通讯作者：
Prokhorov, Alexander V
中科院分区：
文献类型：
--
作者：
Hudmon, Karen Suchanek;Corelli, Robin L;Prokhorov, Alexander V
众所周知，吸烟是美国主要的可预防的疾病和死亡原因，它对广泛的负面健康后果负有责任，包括但不限于呼吸系统疾病。根据美国公共卫生署，应鼓励所有试图戒烟的患者使用一种或多种有效的药物治疗剂戒烟，除非存在特殊情况或有效性证据不足的人群（孕妇、无烟烟草使用者、轻度吸烟者和青少年）。这些药物与行为咨询干预相结合时最有效。这篇综述文章提供了一个全面的概述（5A的框架：问，建议，评估，协助，安排）和简短的（问，建议，参考）干预措施，以帮助患者戒烟，并更详细地审查了七个一线药物戒烟（尼古丁替代疗法配方，安非他酮SR和伐尼克兰）和联合治疗方案。这些信息将有助于呼吸治疗师解决他们所服务的患者人群中最重要的肺部疾病风险因素。
It is well established that smoking is the primary preventable cause of disease and death in the United States and that it is responsible for a wide range of negative health consequences, including but not limited to respiratory disease. According to the US Public Health Service, all patients attempting to quit smoking should be encouraged to use one or more effective pharmacotherapy agents for cessation except in the presence of special circumstances or in populations for which there is insufficient evidence of effectiveness (pregnant women, smokeless tobacco users, light smokers and adolescents). These medications are most effective when coupled with behavioral counseling interventions. This review article provides an overview of comprehensive (the 5 A's framework: Ask, Advise, Assess, Assist, Arrange) and brief (Ask, Advise, Refer) interventions for assisting patients with quitting, and a more detailed review of the seven first-line pharmacological agents for smoking cessation (nicotine replacement therapy formulations, bupropion SR and varenicline) and combination therapy regimens. This information will facilitate respiratory therapists in addressing the most important risk factor for pulmonary disease in the patient population that they serve.